Autopsy report · NCT05486208
A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
Cause of deathFutility
“Study terminated due to lack of efficacy signal in atopic dermatitis participants.”
Life of this trial
- Ran for about 1 year 5 months before it stopped.
- 86 participants enrolled.
- Results were posted on the registry 2 years 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Conditions
- Healthy; Dermatitis, Atopic
- Interventions
- LY3844583; LY3844583; Placebo; Placebo
- Participants
- 86
- Sites
- 3
- Countries
- Japan, United States
Trials that died the same way
- Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
“Study was terminated early due to a lack of improved efficacy.” - A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
“The study was early terminated due to lack of efficacy.” - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.